PRISM BioLab Co. LTD (206A) AI Stock Analysis

PRISM BioLab Co. LTD

(TSE/TYO:206A)

Select Model

Rating:49Neutral

Price Target:JPY 129.00▼(-2.27% Downside)

Action:reiterated

Date:10/02/26

The overall score is driven by a strong, debt-free balance sheet and growing equity base, offset by persistent losses and heavy cash burn that heighten funding and execution risk. Weak technical momentum and an unattractive, loss-driven valuation further pressure the rating, making the stock more suitable for investors with high risk tolerance and a long-term view on its R&D stage profile.

Positive Factors

Rapid Revenue GrowthThe strong recent revenue expansion indicates that PRISM BioLab is generating greater commercial or partnering activity as its programs advance. If this growth persists, it can broaden the company’s funding base and improve operating leverage, although profitability remains unproven.

Negative Factors

Persistent UnprofitabilityPersistent EBIT and net losses show that the recent revenue rebound has not yet translated into a self-sustaining business. Continued losses can constrain internal investment, weaken shareholder value creation, and increase reliance on partnerships or external financing while programs mature.

PRISM BioLab Co. LTD (206A) vs. iShares MSCI Japan ETF (EWJ)

Market Cap: JPY 4.88B
Dividend Yield: ―
Average Volume (3M): 89.57K
Price to Earnings (P/E): -5.6
Beta (1Y): 0.98
Revenue Growth: 84.23%
EPS Growth: 33.14%
Country: Japan
Employees: 35
Sector: General
Sector Strength: 55
Industry: Biotechnology

PRISM BioLab Co. LTD Business Overview & Revenue Model

Company Description

PRISM BioLab Co., LTD. engages in the research and development of pharmaceuticals using its proprietary drug discovery platform, PepMetics Technology. The company's technology focuses on creating peptide mimetic small molecules designed to mimic α-he...

How the Company Makes Money

PRISM BioLab primarily makes money through partnering and licensing its drug discovery programs and related intellectual property to larger pharmaceutical or biotechnology companies. Revenue typically comes from (1) upfront payments received when a c...

PRISM BioLab Co. LTD Financial Statement Overview

Summary

Financials show strong revenue growth and a debt-free, expanding equity base, but deepening net losses and heavy, volatile cash burn create significant profitability and sustainability risk.

Income Statement

45Neutral

Balance Sheet

85Very Positive

Cash Flow

35Negative

Financial statement breakdown
Breakdown	Sep 2025	Sep 2024	Sep 2023	Sep 2022
Income Statement
Total Revenue	677.33M	305.62M	112.93M	554.40M
Gross Profit	269.76M	160.54M	80.31M	535.14M
EBITDA	-831.28M	-1.05B	-488.13M	67.89M
Net Income	-833.70M	-1.05B	-526.91M	72.96M
Balance Sheet
Total Assets	3.09B	4.53B	1.21B	1.74B
Cash, Cash Equivalents and Short-Term Investments	2.92B	4.39B	1.13B	1.69B
Total Debt	0	0	0	0
Total Liabilities	376.86M	1.03B	63.41M	65.23M
Stockholders Equity	2.71B	3.50B	1.15B	1.67B
Cash Flow
Free Cash Flow	-1.53B	-61.55M	-548.40M	97.25M
Operating Cash Flow	-1.47B	150.14M	-513.81M	102.96M
Investing Cash Flow	-69.01M	-244.19M	-40.38M	-7.87M
Financing Cash Flow	33.59M	3.37B	0	110.87M

PRISM BioLab Co. LTD Technical Analysis

Technical Analysis SentimentNegative

Last Price132.00

Price Trends

50DMA156.42Negative

100DMA151.77Negative

200DMA167.64Negative

Market Momentum

MACD-6.84Negative

RSI35.36Neutral

STOCH17.42Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:206A, the sentiment is Negative. The current price of 132.00 is below the 20-day moving average (MA) of 137.45, below the 50-day MA of 156.42, and below the 200-day MA of 167.64, indicating a bearish trend. The MACD of -6.84 indicates Negative momentum. The RSI at 35.36 is Neutral, neither overbought nor oversold. The STOCH value of 17.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:206A.

PRISM BioLab Co. LTD Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

JP:206A against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
JP:206A	49Neutral	JPY 4.89B	-5.57	―	―	84.23%	33.14%
JP:4880	45Neutral	JPY 5.68B	57.55	―	1.75%	-9.94%	―
JP:4978	45Neutral	JPY 13.03B	-26.58	―	―	-18.71%	-246.54%
JP:7774	42Neutral	JPY 25.54B	-58.02	―	―	3.43%	-53.59%
JP:4599	38Underperform	JPY 8.71B	-4.68	―	―	―	4.85%
JP:7776	37Underperform	JPY 7.43B	-6.49	―	―	-56.16%	3.12%

* General Sector Average

Performance Comparison

JP:206A and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
JP:206A	PRISM BioLab Co. LTD	132.00	-5.00	-3.65%
JP:4599	StemRIM Inc.	139.00	-134.00	-49.08%
JP:4880	CellSource Co., Ltd.	286.00	-225.00	-44.03%
JP:4978	ReproCELL Inc.	122.00	-51.00	-29.48%
JP:7774	Japan Tissue Engineering Co., Ltd.	629.00	153.00	32.14%
JP:7776	CellSeed Inc.	188.00	-249.00	-56.98%

PRISM BioLab Co. LTD Corporate Events

PRISM BioLab’s Revenue Rises but Losses Deepen and Equity Shrinks

Aug 14, 2026

PRISM BioLab reported non-consolidated revenue of ¥369 million for the nine months to June 30, 2026, up 19.4% year on year, but continued to post operating and net losses, with net income at a loss of ¥845 million and basic earnings per sha...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 02, 2026

PRISM BioLab Co. LTD AI Stock Analysis